Fruttamed Clinical studies

Clinical Study-3

Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Mal-function

Nutrients. 2017 May 25;9(6). pii: E540. doi: 10.3390/nu9060540
Inada AC1Figueiredo PS2Santos-Eichler RAD3Freitas KC4Hiane PA5Castro AP6Guimarães RCA7


Social, Cultural and economic shifts in the early 19th century resulted in the rapid development of companies that made good profits from technologically-produced commodities. Accordingly, some habits changed in the society, such as the over-consumption of processed and micronutrient-poor foods and devices that gave rise to a sedentary lifestyle. These factors influenced host-microbiome interactions which, in turn, mediated the etiopathogenesis of “new-era” disorders and diseases, which are closely related, such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, hypertension, and inflammatory bowel disease, which are characterized by chronic dys-regulation of metabolic and immune processes. These pathological conditions require novel and effective therapeutic approaches. Morinda citrifolia (noni) is well known as a traditional healing plant due to its huge medicinal properties. Thus, multiple studies have been conducted to understand its bioactive compounds and their mechanisms of action. mainly due to the complexity of the pathophysiology of obesity and its metabolic dysfunction. In this review, we summarize not only the clinical effects, but also important cell signalling pathways in in vivo and in vitro assays of potent bioactive compounds present in Morinda citrifolia  extracts which have been reported in studies of obesity and obesity-associated metabolic dysfunction.